Alkermes Director Shane Cooke Sells $36.1M in ALKS Stock — Exits to Zero Shares
Alkermes director Shane Cooke has sold $36.1M in ALKS stock across 306 transactions, completing a full exit with zero shares remaining after a February 2026 exercise-and-sell.
Shane Cooke, a director at Alkermes (ALKS), has sold $36.1 million in company stock across 306 transactions — and his final February 2026 trade left him with zero shares.
The Numbers
| Metric | Value |
|---|---|
| Career Sell Value | $36.1M |
| Career Buy Value | $229K |
| Total Transactions | 306 |
| Last Transaction | 2026-02-02 |
| Shares Remaining | 0 |
Recent Activity
| Date | Type | Shares | Price | Est. Value |
|---|---|---|---|---|
| 2026-02-02 | Sell | 32,113 | $34.7796 | $1.1M |
| 2026-02-02 | Sell | 29,087 | $34.3382 | $999K |
| 2025-05-31 | Exercise | 8,013 | N/A | $0 |
On February 2, 2026, Cooke exercised 61,200 options at $31.64 and immediately sold all shares in two blocks at $34.34–$34.78, netting approximately $2.1M. This final transaction brought his holdings to exactly zero.
What It Means
Cooke served as a longtime director at the Dublin-based biopharmaceutical company, which specializes in neuroscience and oncology treatments. His $36.1M in career sales against just $229K in purchases reveals a 158:1 sell-to-buy ratio. The complete exit — down to zero shares — is particularly striking for a board member.
A director voluntarily holding zero shares raises governance questions. While many board exits are planned well in advance, the optics for ALKS shareholders are unfavorable. Alkermes has seen steady revenue growth from its schizophrenia drug Lybalvi, but Cooke's total divestiture suggests his investment thesis has concluded.
What to Watch
- Whether Cooke remains on the Alkermes board with zero equity
- Other ALKS insider activity — is Cooke an outlier or part of a trend?
- Alkermes pipeline catalysts and Lybalvi prescription growth
- New board member appointments or equity grant cycles
Related Research
Explore all researchVictory Capital kept mega-cap tech on top in Q4 2025, but the sharper signal was in the secondary moves: large increases in Netflix, Constellation Energy, TSMC and new positions like IQVIA. The next filing will show whether that diversification continues.
Apr 17, 2026
Raymond James used Q4 2025 to keep broad ETF exposure high through VOO, AGG, SPY and IEFA while also adding to sector sleeves such as XLK and XLE. The next filing will show whether that balanced ETF-heavy structure remains the preferred setup.
Apr 17, 2026
Principal’s Q4 2025 filing looked slightly weaker on headline AUM, but the internal rotation was more revealing: Brookfield became a top-ten position, Netflix surged, and the fund cut back in parts of real estate. The next filing will show whether that shift keeps going.
Apr 17, 2026
Nuveen’s Q4 2025 filing stayed large-cap and AI-heavy at the top, but the more revealing addition was a sizable fixed-income sleeve through NXUS and NHYB. The next filing will show whether those credit and bond ETFs remain central or fade back out.
Apr 17, 2026
Janus Henderson kept Nvidia and Microsoft on top in Q4 2025, but the more interesting signal was underneath: new exposure to Intuitive Surgical, Protagonist Therapeutics and other growth-healthcare names. The next filing will show whether that rotation keeps building.
Apr 17, 2026